ArticleOncoimmunology
Evolution of melanoma cross-resistance to CD8
Open access · goldAbstract read
In one paragraph
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next-Generation Approaches.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Sensitivity to immune checkpoint inhibitors in BRAF/MEK inhibitor refractory melanoma.Journal for immunotherapy of cancer · 2025Article
- GSK3β activation is a key driver of resistance to Raf inhibition in BRAF mutant melanoma cells.Oncotarget · 2025Article
- Exploiting temporal aspects of cancer immunotherapy.Nature reviews. Cancer · 2024Review
- SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells.Frontiers in immunology · 2024Article
- Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.International journal of molecular sciences · 2023Review
- Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?Cancer metastasis reviews · 2023Review
- Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.Cellular and molecular life sciences : CMLS · 2023Review
- Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.Frontiers in immunology · 2023Article
- The future of targeted kinase inhibitors in melanoma.Pharmacology & therapeutics · 2022Review
- Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.Current oncology reports · 2022Review
- Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity.Journal for immunotherapy of cancer · 2022Article
- Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue.Frontiers in oncology · 2022Review
- MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated.Frontiers in cell and developmental biology · 2022Article
- Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.American journal of clinical dermatology · 2021Review
- Tumor-infiltrating CD8Drug discovery today · 2021Review
- Effect of antioxidants coenzyme Q10 and β-carotene on the cytotoxicity of vemurafenib against human malignant melanoma.Oncology letters · 2021Article
- Review
- The future of cancer immunotherapy: microenvironment-targeting combinations.Cell research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 1 country.
Natalia PieperDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Anne ZarembaDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Sonia LeonardelliDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Franziska Noelle HarbersDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Marion SchwambornDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Silke LübckeDepartment of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Barbara SchrörsDepartment of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Jolanthe BaingoDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Alexander SchrammMolecular Oncology, Department of Internal Medicine, University Hospital Essen, Germany.
Sebastian HaferkampDepartment of Dermatology, University Hospital Regensburg, Germany.
Ulrike SeifertFriedrich Loeffler Institute of Medical Microbiology, University Medicine Greifswald, Greifswald, Germany.
Antje SuckerDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Volker LennerzDepartment of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Thomas WölfelDepartment of Internal Medicine III, University Medical Center, Johannes Gutenberg University, Mainz, Germany.
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Bastian SchillingDepartment of Dermatology, Venerology and Allergology, University Hospital Würzburg, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Fang ZhaoDepartment of Dermatology, University Hospital Essen, University Duisburg-Essen and German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany.
Düsseldorf University Hospital · DEJohannes Gutenberg University Mainz · DEEssen University Hospital · DEFriedrich-Loeffler-Institut · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Regensburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The profound but frequently transient clinical responses to BRAF
Indexed as
antigensBRAFCD8+ T cellsinhibitorMEKmelanomaresistance
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.